Use of YD-851 in the preparation of a medicament for treating or preventing pulmonary fibrosis

By using YD-851 to inhibit the BRD4 protein, a drug for treating pulmonary fibrosis was developed, which solved the problem of limited efficacy in existing technologies, achieved significant improvement in pulmonary fibrosis, and provided a new treatment strategy.

CN122398795APending Publication Date: 2026-07-17CHONGQING UNIVERSITY THREE GORGES HOSPITAL
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
CHONGQING UNIVERSITY THREE GORGES HOSPITAL
Filing Date
2026-05-22
Publication Date
2026-07-17

AI Technical Summary

Technical Problem

Existing technologies have limited efficacy in treating pulmonary fibrosis, and there is a lack of ideal drugs to significantly control the disease progression. In particular, for idiopathic pulmonary fibrosis (IPF), the cause is unknown and the prognosis is extremely poor, existing drugs have limited efficacy and significant adverse reactions.

Method used

YD-851 is used as a BET bromine domain inhibitor to reduce the expression of fibrosis-related genes by inhibiting BRD4 protein expression, and is developed into a drug for the treatment and/or prevention of pulmonary fibrosis. Dosage forms include tablets, capsules, etc., with a dose of 0.001–2 mg/kg/day.

Benefits of technology

YD-851 significantly improves lung tissue structure, reduces the degree of fibrosis, lowers pulmonary fibrosis and inflammation scores, improves microCT imaging abnormalities and lung function impairment, and provides a new small molecule treatment strategy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122398795A_ABST
    Figure CN122398795A_ABST
Patent Text Reader

Abstract

The application discloses a new use of a BET inhibitor YD-851 or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating pulmonary fibrosis. The application finds that YD-851 can inhibit the expression of BRD4 and fibrosis-related markers in pulmonary fibrosis tissues, reduce the structural damage of bleomycin-induced mouse lung tissues, inflammatory cell infiltration and fibrosis pathological changes, and improve lung function damage. Experimental results show that YD-851 can reduce the pulmonary fibrosis score, inflammation score and area ratio of consolidation, improve the lung imaging abnormalities, and down-regulate the expression of fibrosis-related genes such as Col1a1, Fn1 and Acta2. It is shown that YD-851 has the effect of treating pulmonary fibrosis, and can be used for preparing a drug for treating pulmonary fibrosis, and a new use of YD-851 is developed.
Need to check novelty before this filing date? Find Prior Art